The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | γ9δ2 T-cell activation with ICT01 and azacitidine-venetoclax in patients with newly diagnosed AML
In this video, Abhishek Maiti, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares the findings from a Phase I/II study investigating ICT01, a novel immunotherapy that activates γ9δ2 T-cells, in combination with azacitidine and venetoclax in patients with newly diagnosed acute myeloid leukemia (AML). This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
